Salvia BioElectronics Secures $60M for Innovative Migraine Treatment Device

Dutch neuromodulation developer Salvia BioElectronics has raised $60 million in a Series B funding round to advance its groundbreaking minimally invasive implant for chronic migraine sufferers. The company's MySalvia Therapy system, which has received FDA breakthrough designation, aims to revolutionize migraine treatment through a unique approach to neuromodulation.

Innovative Technology and Clinical Progress

Salvia BioElectronics' device utilizes paper-thin implants placed under the skin at the front and back of the head. These implants deliver electrical impulses to the nervous system and can be activated on-demand by the user via an external wearable device. The company is currently conducting a blinded, sham-controlled study to evaluate the efficacy of this novel treatment approach.

The clinical trial has already enrolled its first patient in the Netherlands, with ongoing recruitment in Belgium and Australia. CEO Hubert Martens emphasized the potential impact of the technology, stating, "Chronic migraine is not 'just a headache.' It is a debilitating neurological condition that forces people out of their social life, their work, and the life they want to live. MySalvia Therapy is designed to provide not just relief, but meaningful and lasting impact."

Funding and Future Plans

The $60 million Series B round was led by Innovation Industries, with participation from a consortium of investors including Invest-NL, EIC Fund, Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency, and Thuja Capital. This substantial investment will support Salvia BioElectronics in its journey towards regulatory approval and commercialization.

Caaj Greebe, partner at Innovation Industries, expressed confidence in the company's approach: "Salvia BioElectronics is redefining the migraine therapy landscape with a bold, patient-centered approach that combines cutting-edge neuromodulation with an elegant, minimally invasive design."

Expanding Horizons

While the current focus is on chronic migraine treatment, Salvia BioElectronics is also exploring the potential of its technology for addressing cluster headaches. The company plans to initiate a U.S. study in the future, further expanding its clinical research efforts.

The MySalvia system's design aims to overcome limitations of previous neuromodulation approaches by being less invasive and visually discreet. This patient-friendly approach could potentially benefit millions of individuals affected by chronic migraines, offering hope for improved quality of life and reduced disability associated with this challenging neurological condition.